NDRA

MKT CAP:$4M

ENDRA Life Sciences Inc.

Market Cap

$4M

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$5.00+$0.71 (+16.55%)

Apr 23, 2026

Company Details

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs,...

CEO

Alexander Y. Tokman

IPO Date

Jun 30, 2017

Website

www.endrainc.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$7M

EPS (Diluted)

-$8.93

Free Cash Flow

-$8M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 31, 2026

$0EPS -$8.93

Q4 2025

Mar 31, 2026

$0EPS -$3.26

Q3 2025

Nov 14, 2025

$0EPS -$2.10

Q2 2025

Aug 14, 2025

$0EPS -$1.71

Q1 2025

May 15, 2025

$0EPS -$1.86

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$52.2K	-$3M
Q2 22	$0	-$55.7K	-$4M
Q3 22	$0	-$58.6K	-$3M
Q4 22	$0	-$67.8K	-$3M
Q1 23	$0	-$71.0K	-$3M
Q2 23	$0	-$72.7K	-$3M
Q3 23	$0	-$70.4K	-$3M
Q4 23	$0	-$61.2K	-$1M
Q1 24	$0	-$55.7K	-$3M
Q2 24	$0	-$50.1K	-$2M
Q3 24	$0	$0	-$2M
Q4 24	$0	-$46.4K	-$4M
Q1 25	$0	-$45.6K	-$1M
Q2 25	$0	-$32.8K	-$1M
Q3 25	$0	-$39.4K	-$1M
Q4 25	$0	-$39.5K	-$2M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$3M	-$3M
Q2 22	-$3M	-$3M
Q3 22	-$3M	-$3M
Q4 22	-$3M	-$3M
Q1 23	-$3M	-$3M
Q2 23	-$2M	-$2M
Q3 23	-$3M	-$3M
Q4 23	-$2M	-$2M
Q1 24	-$2M	-$2M
Q2 24	-$2M	-$2M
Q3 24	-$2M	-$2M
Q4 24	-$2M	-$2M
Q1 25	-$1M	-$1M
Q2 25	-$1M	-$1M
Q3 25	-$1M	-$1M
Q4 25	-$2M	-$5M

Capital Expenditures

Quarter	CapEx
Q1 22	$89.4K
Q2 22	$59.8K
Q3 22	$14.9K
Q4 22	$38.6K
Q1 23	$27.0K
Q2 23	$0
Q3 23	$0
Q4 23	$6.9K
Q1 24	$27.0K
Q2 24	$11.0K
Q3 24	$0
Q4 24	$0
Q1 25	$17.3K
Q2 25	$0
Q3 25	$0
Q4 25	$3M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+10.8%
Q2 22	—	+11.6%
Q3 22	—	+28.9%
Q4 22	—	+7.9%
Q1 23	—	+2.9%
Q2 23	—	-16.2%
Q3 23	—	-8.4%
Q4 23	—	-56.0%
Q1 24	—	-5.4%
Q2 24	—	-25.5%
Q3 24	—	-51.8%
Q4 24	—	+194.7%
Q1 25	—	-47.2%
Q2 25	—	-41.7%
Q3 25	—	-9.2%
Q4 25	—	-62.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$288.5K	—
Q2 22	$311.3K	—
Q3 22	$309.2K	—
Q4 22	$290.8K	—
Q1 23	$237.3K	—
Q2 23	$255.9K	—
Q3 23	$252.7K	—
Q4 23	$250.6K	—
Q1 24	$317.5K	—
Q2 24	$186.6K	—
Q3 24	-$36.8K	—
Q4 24	$104.7K	—
Q1 25	$83.0K	—
Q2 25	$88.8K	—
Q3 25	$144.7K	—
Q4 25	$12.9K	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$1M	—	—	$2M
Q2 22	$2M	—	—	$2M
Q3 22	$2M	—	—	$2M
Q4 22	$2M	—	—	$2M
Q1 23	$1M	—	—	$1M
Q2 23	$1M	—	—	$2M
Q3 23	$2M	—	—	$1M
Q4 23	$579.4K	—	—	$817.2K
Q1 24	$1M	—	—	$2M
Q2 24	$716.4K	—	—	$1M
Q3 24	$794.4K	$631.4K	$83.2K	—
Q4 24	$638.0K	—	—	$4M
Q1 25	$528.7K	—	—	$895.0K
Q2 25	$381.1K	—	—	$887.2K
Q3 25	$432.1K	$893.3K	$45.3K	—
Q4 25	$508.1K	$1M	$6.4K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$7M	$0	$7M
Q2 22	$11M	$0	$11M
Q3 22	$8M	$0	$8M
Q4 22	$5M	$0	$5M
Q1 23	$2M	$0	$2M
Q2 23	$5M	$0	$5M
Q3 23	$3M	$0	$3M
Q4 23	$3M	$0	$3M
Q1 24	$1M	$0	$1M
Q2 24	$6M	$0	$6M
Q3 24	$5M	$0	$5M
Q4 24	$3M	$0	$3M
Q1 25	$2M	$0	$2M
Q2 25	$2M	$0	$2M
Q3 25	$794.0K	$0	$794.0K
Q4 25	$762.4K	$0	$762.4K

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	2M	+2.7%	+14.0%
Q2 22	2M	-10.3%	-7.4%
Q3 22	2M	0.0%	-7.9%
Q4 22	2M	0.0%	-7.9%
Q1 23	2M	0.0%	-10.3%
Q2 23	2M	-11.5%	-11.5%
Q3 23	2M	0.0%	-11.5%
Q4 23	2M	0.0%	-11.5%
Q1 24	2M	0.0%	-11.5%
Q2 24	2M	0.0%	0.0%
Q3 24	1M	-34.3%	-34.3%
Q4 24	537K	-52.2%	-68.6%
Q1 25	558K	+3.9%	-67.4%
Q2 25	717K	+28.6%	-58.0%
Q3 25	761K	+6.2%	-32.2%
Q4 25	787K	+3.4%	+46.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	22
Q2 22	$0	22
Q3 22	$0	22
Q4 22	$0	21
Q1 23	$0	21
Q2 23	$0	21
Q3 23	$0	21
Q4 23	$0	21
Q1 24	$0	21
Q2 24	$0	21
Q3 24	$0	21
Q4 24	$0	21
Q1 25	$0	21
Q2 25	$0	21
Q3 25	$0	21
Q4 25	$0	11

Revenue / Employee